 |
Aditya Birla Sun Life Nifty Healthcare ETF |
| An open ended exchange traded fund tracking Nifty Healthcare TRI BSE Scrip Code: 543473 | Symbol: HEALTHY |
| Data as on 30th September 2024 |
 |
Fund Details |
|
 |
 |
 |
Investment Objective |
| The investment objective of the scheme is to provide returns that before expenses, closely correspond to the total returns of securities as represented by Nifty Healthcare TRI, subject to tracking errors. However, the performance of scheme may differ from that of the underlying index due to tracking error.The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved. | |
 |
| Fund Manager | |
|---|---|
| Mr. Haresh Mehta |
| Managing Fund Since | |
|---|---|
| March 31, 2023 |
| Experience in Managing the Fund | |
|---|---|
| 1.5 Years |
| Load Structure (as % of NAV) (Incl. for SIP) | |
|---|---|
| Entry Load | Nil |
| Exit Load | Nil |
| Total Expense Ratio (TER) | |
|---|---|
| Regular | 0.22% |
| Including additional expenses and goods and service tax on management fees. | |
| Tracking Error | |
|---|---|
| Regular | 0.55% |
| AUM ₹ | |
|---|---|
| Monthly Average AUM | 39.18 Crores |
| AUM as on last day | 39.61 Crores |
| Date of Allotment | |
|---|---|
| October 20, 2021 |
| Benchmark | |
|---|---|
| Nifty Healthcare TRI |
| Minimum Application Amount: | |
|---|---|
| For Transactions Directly with the Fund: | |
| For Market Makers: | The Creation Unit size for the Scheme shall be 1,10,000 units and in multiples thereof. |
| For Large Investors: | Min. application amount shall be Rs. 25 Crores and in multiples of Creation Unit Size |
| For Transactions on Stock Exchanges: | |
|---|---|
| Units of ETF scheme can be traded (in lots of 1 Unit) during the trading hours on all trading days on NSE and BSE on which the Units are listed. |
 NAV ₹ |
|---|
| 15.0812 |
|
PORTFOLIO |
|
| Issuer | % to Net Assets |
| Pharmaceuticals & Biotechnology | 80.17% |
| Sun Pharmaceutical Industries Limited | 22.80% |
| Cipla Limited | 9.52% |
| Dr. Reddys Laboratories Limited | 9.01% |
| Divi's Laboratories Limited | 7.60% |
| Lupin Limited | 5.80% |
| Aurobindo Pharma Limited | 4.50% |
| Torrent Pharmaceuticals Limited | 3.40% |
| Alkem Laboratories Limited | 3.33% |
| Zydus Lifesciences Limited | 2.95% |
| Glenmark Pharmaceuticals Limited | 2.74% |
| IPCA Laboratories Limited | 2.21% |
| Issuer | % to Net Assets |
| Laurus Labs Limited | 2.00% |
| Biocon Limited | 1.77% |
| Abbott India Limited | 1.69% |
| Granules India Limited | 0.83% |
| Healthcare Services | 19.66% |
| Max Healthcare Institute Limited | 7.98% |
| Apollo Hospitals Enterprise Limited | 7.94% |
| Syngene International Limited | 1.78% |
| Dr. Lal Path Labs Limited | 1.33% |
| METROPOLIS HEALTHCARE LIMITED | 0.62% |
| Cash & Current Assets | 0.17% |
| Total Net Assets | 100.00% |
Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes managed by Mr. Haresh Mehta is 17. Click here to know more on performance of schemes managed by Fund Managers.
Standard deviation of daily tracking difference computed for a 1 year horizon. If the fund is non-existent for 1 year then since inception returns are considered.
Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.
